Insmed – Talk Bio

Insmed’s ‘Unprecedented’ Phase 2 PAH Results Propel Stock and Next-Phase Plans

1 month ago talkbio0Tagged Clinical Trials, Insmed, PAH, Phase 3 trial, Pulmonary arterial hypertension, surge, TPTE2 gene, treprostinil palmitil inhalation powder

Insmed; PAH; TPIP; Phase 2b; clinical trial; treprostinil palmitil inhalation powder; stock surge; pulmonary arterial hypertension; Phase 3 trial; biotech

Insmed’s TPIP PAH Therapy Advances to Phase III Following Positive Phase 2b Results

2 months ago talkbio0Tagged Clinical Trials, Engaged to be married, Insmed, PAH, Phase 3 Clinical Trials, Pulmonary arterial hypertension, TPTE2 gene, treprostinil palmitil inhalation powder, United States Food and Drug Administration

Insmed; TPIP; treprostinil palmitil inhalation powder; pulmonary arterial hypertension; PAH; Phase 2b trial; Phase III trial; clinical trial results; FDA engagement

Insmed’s Stocks Skyrocket Following Triumphant Phase III Results for Brensocatib in Bronchiectasis Treatment

1 year ago talkbio0Tagged Approved, brensocatib, Bronchiectasis, Insmed, Lung diseases, Market, New Drug Application, Phase 3 Clinical Trials, surge, United States Food and Drug Administration

Insmed, brensocatib, bronchiectasis, Phase III trial, lung disease, stock surge, New Drug Application, FDA approval, market value